Uveitis Induced by Brentuximab Vedotin-A Novel Adverse Response to Antibody-Drug Conjugate Therapy

Gal Antman^1*, Gali Abrahami², Ori Berliner¹, Rita Erlich^1,3, Ehud Reich^1,3, Michal Kramer^1,3 and Yael Sharon¹

¹Department of Ophthalmology, Rabin Medical Center, Petah, Tikva, Israel

²Department of Pediatric Hemato-Oncology, Schneider Children’s Medical Center of Israel, Petah, Tikva, Israel

³Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

*Corresponding Author : Gal Antman, Department of Ophthalmology
Rabin Medical Center, Petah-Tikva, Israel
E-mail: Antmangal@gmail.com

Received: March 06, 2021 Accepted: November 16, 2021 Published: December 03, 2021

Citation: Antman G, Abrahami G, Berliner O, Erlich R, Reich E, et al. (2021) Uveitis Induced by Brentuximab Vedotin-A Novel Adverse Response to Antibody- Drug Conjugate Therapy. Clin Oncol Case Rep 4:12.

Purpose: To report a novel ocular inflammatory adverse event to brentuximab vedotin, an anti-CD-30 agent, in a young patient with Hodgkin’s lymphoma. Methods: Case report Results: A 19-year-old female presented with bilateral profound decreased vision due to anterior and intermediate uveitis while being treated with brentuximab, for recurrence of Hodgkin’s lymphoma. Treatment with brentuximab was halted and the patient was treated with intravenous steroids and improved dramatically. Infectious and masquerade etiologies were ruled out. Conclusion: This is the first report of an ocular inflammatory adverse event to brentuximab as a monotherapy. Despite its rarity, ocular responses to biologic agents should be added to the differential diagnosis of intraocular inflammation and treating physicians should be aware of this potential side effect. It is suggested that the American Society of Clinical Oncology Guidelines for the management of immune-related adverse events in patients treated with immune checkpoint inhibitor agents be employed in these cases as well.